Lemborexant
- Generic Name
- Lemborexant
- Brand Names
- Dayvigo
- Drug Type
- Small Molecule
- Chemical Formula
- C22H20F2N4O2
- CAS Number
- 1369764-02-2
- Unique Ingredient Identifier
- 0K5743G68X
- Background
Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to "switc...
- Indication
Lemborexant is indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance.
- Associated Conditions
- Insomnia
- Associated Therapies
- -
A Study of Lemborexant in Chinese Participants With Insomnia Disorder
- Conditions
- Interventions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 194
- Registration Number
- NCT04549168
- Locations
- 🇨🇳
Beijing Tiantan Hosptial, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of Lemborexant-Alcohol Interaction in Healthy Subjects
- First Posted Date
- 2018-03-30
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03483636
- Locations
- 🇨🇦
Syneos Health, Toronto, Ontario, Canada
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03451110
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT03440424
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03443063
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2020-02-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 971
- Registration Number
- NCT02952820
- Locations
- 🇵🇱
Facility # 2, Warszawa, Poland
🇯🇵Eisai Trial Site 3, Yokohama, Kanagawa, Japan
🇯🇵Eisai Trial Site 2, Yokohama, Kanagawa, Japan
Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)
- Conditions
- Interventions
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1006
- Registration Number
- NCT02783729
- Locations
- 🇺🇸
Saint Francis Sleep Allergy and Lung Institute, Clearwater, Florida, United States
🇨🇦Toronto Sleep Institute, Toronto, Ontario, Canada
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.